Summary
The kinetics of cibenzoline (UP 339.01), a new antiarrhythmic drug, was studied after i.v. and oral administration to 5 healthy subjects. Cibenzoline levels in plasma and urine cibenzoline were measured by a GLC method. After i.v. administration, the total clearance was 826 ml · min−1. The fraction of cibenzoline excreted unchanged in the urine was 0.602 and it was correlated with the creatinine clearance. After i.v. and oral administration, the renal clearances were 499 ml · min−1 and 439 ml · min−1, and the half-lives were 4 h 01 min and 3 h 24 min, respectively. The differences were not significant. Availability by the oral route was 0.92, the maximum plasma concentration being observed at 1 h 36 min. The results were compared with those for other antiarrhythmic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baligadoo S, Chiche P (1978) Benefical effect of UP339-01 a new antiarrhythmic agent against ventricular premature beats. Circulation 58: 692
Boxembaum HG, Riegelman S, Elashoff RM (1974) Statistical estimation in pharmacokinetics. J Pharmacokinet Biopharm 2: 123–148
Boyes RN, Scott DB, Jebson PJ, Dogman MJ, Julian DG (1971) Pharmacokinetics of lidocaïne in man. Clin Pharmacol Ther 12: 105–116
Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Progr Pharmacol 1: 9–34
Giardina EGV, Dreyfuss J, Bigger JT, Shaw JM, Schreiber EC (1976) Metabolism of procaïmide in normal and cardiac subjects. Clin Pharmacol Ther 19: 339–351
Gibson TP, Lowenthal DT, Nelson HA, Briggs WA (1975) Elimination of procaïnamide in end stage renal failure. Clin Pharmacol Ther 17: 321–329
Graffner C, Johnsson G, Sjogren J (1975) Pharmacokinetics of procaïnamide intravenously and orally as conventional and slow-release tablets. Clin Pharmacol Ther 17: 414–423
Guentert TW, Holford NHG, Coates PE, Upton RA, Riegelman S (1979) Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm 7: 315–330
Haselbarth V, Doevendans JE, Wolf M (1981) Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 29: 729–736
Henry JA, Johnston A, Warrington SJ, Hamer NA (1979) Influence of renal failure on disopyramide pharmacokinetics. Br J Clin Pharmacol 7: 427–428
Herpin D, Gaudeau B, Boutaud P, Amiel A, Tourdias B, Demange J (1981) Clinical trial of a new anti-arrhythmic drug: Cibenzoline (Cipralan®). Curr Ther Res 30: 742–752
Hinderling PH, Garret ER (1976) Pharmacokinetics of the antiarrhythmic disopyramide in healthy human. J Pharmacokinet Biopharm 4: 199–230
Johnston A, Henry JA, Warrington SJ, Hamer NAJ (1980) Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. Br J Clin Pharmacol 10: 245–248
Klotz U, Muller-Seydlitz P, Heimburg P (1978) Pharmacokinetics of lorcaïnide in man: a new antiarrhythmic agent. Clin Pharmacokinet 3: 407–418
Koch Weser J, Klein SW (1971) Procaïnamide dosage schedules. J Am Med Assoc 215: 1454–1460
Mather LE, Thomas J (1972) Metabolism of lidocaïne in man. Life Sci 11: 915–919
Millar JS, Vaughan Williams EM (1982) Effect on rabbit nodal, atrial, ventricular and purkinje cell potentials of a new antiarrhythmic drug, cibenzoline which protects against action potential shortening in hypoxia. Br J Pharmacol 75: 469–478
Rowland M (1972) Influence of route of administration on drug availability. J Pharm Sci 61: 70–74
Thebaut JF, Achard F, de Langenhagen B (1980) Etude électrophysiologique chez l'homme d'un nouvel antiarythmique, la cibenzoline, dans le syndrome de Wolff-Parkinson-White. Inf Cardiol 4: 393–402
Thizy JF, Jandot V, Andre-Fouet X, Viallet M, Pont M (1981) Etude électrophysiologique de l'UP339-01 chez l'homme. Lyon Med 245: 119–122
Ueda CT, Hirschfeld DS, Scheinman MM, Rowland M, Williamson BJ, Dzindzio BS (1976) Disposition kinetics of quinidine. Clin Pharmacol Ther 19: 30–36
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, IL
Wagner JG (1976) Linear pharmacokinetic equation allowing direct calculation of many needed pharmacokinetic parameter from the coefficient and exponents of poly exponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4: 443–467
Weily MS, Genton E (1972) Pharmacokinetics of procaïnamide. Arch Intern Med 130: 366–369
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Canal, M., Flouvat, B., Tremblay, D. et al. Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline. Eur J Clin Pharmacol 24, 509–515 (1983). https://doi.org/10.1007/BF00609894
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609894